Luye Pharma Group Ltd is to acquire the TDS business from Acino through the purchase of the entire issued share capital of Acino AG and Acino Supply AG for €245m. The target group is a Europe-based leader in advanced transdermal drug delivery systems (TDS) and is one of the largest independent TDS manufacturers in Europe. Closing is expected to occur in the second half of 2016.
Walder Wyss comprehensively advised Luye regarding the Swiss law aspects of this transaction. The team was led by Alexander Gutmans (Partner, Corporate/M&A) and Robert von Rosen (Managing Associate, Corporate) and also included Dirk Spacek (Associate, IP/IT) and Jessica Aeschbach Flórez (Associate, Corporate).
